ストックスクリーナーアプリを入手
14.07
35.94%
-7.895
Sarepta Therapeutics Inc (SRPT) 最新ニュース
What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional
Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
What drives Sarepta Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance
Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com
Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha
Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest
M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World
Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV
Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire
Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters
Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News
Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire
Sarepta receives FDA request to halt ELEVIDYS shipments for some patients - StreetInsider
Sarepta Says Another Patient Died After Receiving Gene Therapy - Bloomberg
FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths - NeurologyLive
Sarepta Therapeutics Provides Statement on ELEVIDYS - Sarepta Therapeutics
Gene-therapy company to eliminate 21 Durham employees as part of major restructuring - WRAL.com
HHS Says FDA Requests Sarepta Therapeutics Suspend Distribution Of Elevidys And Places Clinical Trials On Hold For Multiple Gene Therapy Products Following 3 Deaths - TradingView
FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy - The Boston Globe
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - MarketScreener
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - Reuters
Sarepta Therapeutics laying off 80 employees in Ohio - WTTE
Sarepta Therapeutics crisis is huge blow to Duchenne families, company - statnews.com
Major biotech stock tumbles 35 percent after major rare disease setback - TheStreet
Sarepta Crashes Almost 40% On A Damning Move From The FDA - Investor's Business Daily
Elevidys' future said to be on ice after Sarepta reports patient death from separate gene therapy - FirstWord Pharma
FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys - The New York Times
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - TradingView
Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths - TipRanks
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire Inc.
Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns - Investing.com
FDA mulls Elevidys market withdrawal following 3rd death after Sarepta gene therapy - Fierce Pharma
Sarepta shares plunge 30% as future of its gene therapy appears at risk - MSN
Sarepta Shares Crash on Report That FDA Will Ask It to Stop Shipping Drug - Barron's
Sarepta Craters as FDA Considers Requesting Halt to Elevidys Shipments - BioSpace
FDA to ask Sarepta to stop shipping Duchenne gene therapy - BioPharma Dive
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments (SRPT) - Seeking Alpha
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty' - StreetInsider
Strategic Restructure and ELEVIDYS Label Update Call (NASDAQ:SRPT) - Seeking Alpha
Sarepta falls as FDA mulls Elevidys' future (update) (SRPT) - Seeking Alpha
Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says - Reuters
Sarepta shares plunge 40% as future of its gene therapy appears at risk - CNBC
Sarepta Therapeutics stock hits 52-week low at 16.87 USD By Investing.com - Investing.com South Africa
Sarepta share price drops again after third gene therapy death - Yahoo Finance
FDA asks Sarepta to stop shipping gene therapy after patient deaths. Sarepta says no. - The Business Journals
Sarepta Therapeutics stock hits 52-week low at 16.87 USD - Investing.com Australia
0.59%
0.34%
大文字化:
|
ボリューム (24 時間):